Brief: Neovacs Presents Phase IIb Ifnalpha Kinoid Clinical Study Results

Neovacs SA

24/01/2019 16:53

Jan 24 (Reuters) - NEOVACS SA  ALNEV.PA :
    * TO PRESENT FULL RESULTS FROM THE PHASE IIB IFNALPHA KINOID
CLINICAL STUDY AT THE 13TH INTERNATIONAL LUPUS CONGRESS
    * AN IMMUNE RESPONSE ACHIEVED WITH 91% OF PATIENTS TREATED
WITH
IFNΑ KINOID
    * STATISTICALLY SIGNIFICANT EFFICACY IN REDUCTION OF
INTERFERON
SIGNATURE
    * A STATISTICALLY SIGNIFICANT CLINICAL EFFICACY ON LLDAS
SCORE
    * FAVORABLE SAFETY PROFILE OF TREATMENT BASED ON THESE
RESULTS,
NEOVACS HAS LAUNCHED PREPARATION OF PHASE III CLINICAL
DEVELOPMENT PROGRAM

Source text for Eikon:  ID:nGNE34vNC8 
Further company coverage:  ALNEV.PA 

 (Gdynia Newsroom)
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))